|
1
|
Abdalla MMI. Role of visfatin in obesity-induced insulin resistance. World J Clin Cases 2022; 10:10840-10851. [PMID: 36338223 PMCID: PMC9631142 DOI: 10.12998/wjcc.v10.i30.10840] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Revised: 06/13/2022] [Accepted: 09/23/2022] [Indexed: 02/05/2023] Open
Abstract
The growing worldwide burden of insulin resistance (IR) emphasizes the importance of early identification for improved management. Obesity, particularly visceral obesity, has been a key contributing factor in the development of IR. The obesity-associated chronic inflammatory state contributes to the development of obesity-related comorbidities, including IR. Adipocytokines, which are released by adipose tissue, have been investigated as possible indicators of IR. Visfatin was one of the adipocytokines that attracted attention due to its insulin-mimetic activity. It is released from a variety of sources, including visceral fat and macrophages, and it influences glucose metabolism and increases inflammation. The relationship between visfatin and IR in obesity is debatable. As a result, the purpose of this review was to better understand the role of visfatin in glucose homeostasis and to review the literature on the association between visfatin levels and IR, cardiovascular diseases, and renal diseases in obesity.
Collapse
Affiliation(s)
- Mona Mohamed Ibrahim Abdalla
- Physiology Department, Human Biology Division, School of Medicine, International Medical University, Kuala Lumpur 57000, Bukit Jalil, Malaysia
| |
Collapse
|
|
2
|
Li J, Chen Z, Chen J, Yu Y. The beneficial roles of apelin-13/APJ system in cerebral ischemia: Pathogenesis and therapeutic strategies. Front Pharmacol 2022; 13:903151. [PMID: 36034795 PMCID: PMC9399844 DOI: 10.3389/fphar.2022.903151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Accepted: 07/18/2022] [Indexed: 12/04/2022] Open
Abstract
The incidence of cerebral ischemia has increased in the past decades, and the high fatality and disability rates seriously affect human health. Apelin is a bioactive peptide and the ligand of the G protein-coupled receptor APJ. Both are ubiquitously expressed in the peripheral and central nervous systems, and regulate various physiological and pathological process in the cardiovascular, nervous and endocrine systems. Apelin-13 is one of the subtypes of apelin, and the apelin-13/APJ signaling pathway protects against cerebral ischemia by promoting angiogenesis, inhibiting excitotoxicity and stabilizing atherosclerotic plaques. In this review, we have discussed the role of apelin-13 in the regulation of cerebral ischemia and the underlying mechanisms, along with the therapeutic potential of the apelin-13/APJ signaling pathway in cerebral ischemia.
Collapse
Affiliation(s)
- Jiabin Li
- Department of Pharmacy, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
| | - Zhang Chen
- Department of Tuina, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
| | - Jingyu Chen
- Department of Critical Care Medicine, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
- *Correspondence: Jingyu Chen, ; Yue Yu,
| | - Yue Yu
- Department of Critical Care Medicine, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China
- *Correspondence: Jingyu Chen, ; Yue Yu,
| |
Collapse
|
|
3
|
Chondrogianni M, Lambadiari V, Katsanos AH, Stefanou MI, Palaiodimou L, Triantafyllou AS, Karagiannis G, Konstantakos V, Ioakeimidis M, Triantafyllou S, Zompola C, Liantinioti C, Pappa A, Rizos I, Voumvourakis K, Tsivgoulis G, Boutati E. Omentin Is Independently Associated with Stroke Severity and Ipsilateral Carotid Artery Stenosis in Patients with Acute Cerebral Ischemia. J Clin Med 2021; 10:jcm10245797. [PMID: 34945092 PMCID: PMC8703878 DOI: 10.3390/jcm10245797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 11/27/2021] [Accepted: 12/09/2021] [Indexed: 11/16/2022] Open
Abstract
Mounting evidence indicates an association between adipokines and inflammation-related atherosclerosis. Here, we sought to investigate the association of vaspin and omentin with clinical characteristics and outcomes of patients with acute cerebral ischemia (ACI). Consecutive ACI patients were evaluated within 24 h from symptom-onset. Stroke aetiology was classified using TOAST criteria. Adipokines were assayed using quantikine enzyme immunoassay commercially available kits. Stroke severity was assessed by NIHSS-score, and ipsilateral carotid stenosis (≥50% by NASCET criteria) by ultrasound and CT/MR angiography. Major cerebrovascular events were assessed at three months. We included 135 ACI patients (05 (78%) and 30 (22%) with acute ischemic stroke and transient ischemic attack, respectively; mean age ± SD: 59 ± 10 years; 68% men; median NIHSS-score: 3 (IQR:1–7)). Omentin was strongly correlated to admission stroke severity (Spearman rho coefficient: +0.303; p < 0.001). Patients with ipsilateral carotid stenosis had higher omentin levels compared to patients without stenosis (13.3 ± 8.9 ng/mL vs. 9.5 ± 5.5 ng/mL, p = 0.014). Increasing omentin levels were independently associated with higher stroke severity (linear regression coefficient = 0.290; 95%CI: 0.063–0.516; p = 0.002) and ipsilateral carotid stenosis (linear regression coefficient = 3.411; 95%CI: 0.194–6.628; p = 0.038). No association of vaspin with clinical characteristics and outcomes was found. Circulating omentin may represent a biomarker for the presence of atherosclerotic plaque, associated with higher stroke severity in ACI patients.
Collapse
Affiliation(s)
- Maria Chondrogianni
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
| | - Vaia Lambadiari
- Second Department of Internal Medicine, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (V.L.); (E.B.)
| | - Aristeidis H. Katsanos
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
- Division of Neurology, McMaster University and Population Health Research Institute, Hamilton, ON L8S 3L8, Canada
| | - Maria Ioanna Stefanou
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
| | - Lina Palaiodimou
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
| | - Alexandros Stavros Triantafyllou
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
| | - Georgios Karagiannis
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
| | - Vasileios Konstantakos
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
| | - Michael Ioakeimidis
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
| | - Sokratis Triantafyllou
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
| | - Christina Zompola
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
| | - Chryssa Liantinioti
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
| | - Alexandra Pappa
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
| | - Ioannis Rizos
- Second Department of Cardiology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece;
| | - Konstantinos Voumvourakis
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
| | - Georgios Tsivgoulis
- Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (M.C.); (A.H.K.); (M.I.S.); (L.P.); (A.S.T.); (G.K.); (V.K.); (M.I.); (S.T.); (C.Z.); (C.L.); (A.P.); (K.V.)
- Department of Neurology, University of Tennessee Health Science Center, Memphis, TN 38163, USA
- Correspondence: ; Tel.: +30-6937178635; Fax: +30-2105832471
| | - Eleni Boutati
- Second Department of Internal Medicine, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 124 62 Athens, Greece; (V.L.); (E.B.)
| |
Collapse
|
|
4
|
Zhu B, Yan L, Ren H, Li Q, Chen X. Predictive Value of Apelin and Vaspin on Hemorrhagic Transformation in Patients with Acute Ischemic Stroke after Intravenous Thrombolysis and Analysis of Related Factors. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE : ECAM 2021; 2021:5020622. [PMID: 34707670 PMCID: PMC8545532 DOI: 10.1155/2021/5020622] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Accepted: 09/29/2021] [Indexed: 12/19/2022]
Abstract
BACKGROUND Acute ischemic stroke (CIS) is a high-risk condition among the elderly, and intravenous thrombolytic therapy (ITT) is the most effective means for it. However, ITT is prone to induce hemorrhagic transformation (HT) that further threatens the life and health of patients. As paramount substances in cardiovascular and cerebrovascular diseases, adipocyte factor (Apelin) and serine protease inhibitor (Vaspin) are strongly bound up with CIS. OBJECTIVE To analyze the predictive significance of Apelin and Vaspin on HT in CIS patients after ITT and offer effective reference to HT prevention in the future. METHODS A total of 109 CIS patients treated with intravenous thrombolysis (IT) in two hospitals between June 2017 and February 2018 were enrolled. Among them, 48 patients who suffered HT after therapy were assigned to the research group (Res group) and the other 61 patients who did not suffer it after therapy were assigned to the control group (Con group). Serum Apelin, Vaspin, inflammatory factors, and oxidative stress levels were quantified, and receiver operating characteristic (ROC) curves were drawn for analyzing the predictive value of Apelin and Vaspin on HT after ITT and their associations with inflammatory factors and oxidative stress. CIS patients who suffered HT were followed up for 3 years for prognostic significance analysis of Apelin and Vaspin. RESULTS After ITT, the Res group showed lower Apelin and Vaspin levels than the Con group (all P < 0.05), and patients with a higher HT grade had lower Apelin and Vaspin levels (all P < 0.05). The joint detection of Apelin and Vaspin showed a sensitivity of 77.08% and a specificity of 73.77% for forecasting HT in CIS patients after thrombolytic therapy (all P < 0.001). In addition, after thrombolytic therapy, the Res group presented higher levels of interleukin-1β (IL-1β) and IL-6 as well as malondialdehyde (MDA) than the Con group, and the levels had negative associations with Apelin and Vaspin (all P < 0.05). The Res group showed a lower superoxide dismutase (SOD) level than the Con group, and the level presented a positive association with Apelin and Vaspin (all P < 0.05). According to Logistic analysis, IL-1β, IL-6, and MDA were independent risk factors for HT in CIS patients after IT, while Apelin, Vaspin, and SOD were independent protective factors (all P < 0.05). According to the follow-up results, Apelin and Vaspin demonstrated excellent value in forecasting the death of patients with both CIS and HT (P < 0.05), and their lower levels indicate a higher risk of death (all P < 0.05). CONCLUSION Apelin and Vaspin can help effectively forecast the occurrence of HT in CIS patients after ITT as independent protective factors of HT, so they are of a high clinical application value.
Collapse
Affiliation(s)
- Benju Zhu
- Department of Neurology, Shanghai Eighth People's Hospital, Shanghai 200235, China
| | - Lili Yan
- Department of Neurology, Kailuan General Hospital, Tangshan 067000, Hebei, China
| | - Haiyan Ren
- Department of Neurology, Shanghai Eighth People's Hospital, Shanghai 200235, China
| | - Qiang Li
- Department of Neurology, Shanghai Eighth People's Hospital, Shanghai 200235, China
| | - Xu Chen
- Department of Neurology, Shanghai Eighth People's Hospital, Shanghai 200235, China
| |
Collapse
|